Cerulean Pharma Inc. (NASDAQ:CERU)‘s stock had its “market perform” rating restated by equities researchers at Leerink Swann in a research note issued to investors on Wednesday.

A number of other brokerages have also recently commented on CERU. Zacks Investment Research upgraded shares of Cerulean Pharma from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Wednesday, October 5th. Barclays PLC dropped their price objective on Cerulean Pharma from $5.00 to $2.00 and set an “overweight” rating for the company in a research note on Tuesday, August 30th. Janney Montgomery Scott lowered Cerulean Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday, August 18th. Wedbush lowered Cerulean Pharma from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 18th. Finally, Roth Capital reissued a “buy” rating and set a $2.50 price objective (down previously from $9.00) on shares of Cerulean Pharma in a research note on Thursday, August 18th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Cerulean Pharma has a consensus rating of “Buy” and an average target price of $7.78.

Analyst Recommendations for Cerulean Pharma (NASDAQ:CERU)

Shares of Cerulean Pharma (NASDAQ:CERU) traded up 45.1087% during mid-day trading on Wednesday, reaching $0.9879. 13,921,344 shares of the company’s stock were exchanged. The firm’s market capitalization is $27.05 million. Cerulean Pharma has a one year low of $0.67 and a one year high of $4.33. The stock has a 50-day moving average of $0.96 and a 200 day moving average of $2.14.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/cerulean-pharma-inc-ceru-earns-market-perform-rating-from-leerink-swann.html

Cerulean Pharma (NASDAQ:CERU) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. On average, analysts forecast that Cerulean Pharma will post ($1.58) EPS for the current fiscal year.

A hedge fund recently raised its stake in Cerulean Pharma stock. Vanguard Group Inc. raised its position in Cerulean Pharma Inc. (NASDAQ:CERU) by 43.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 542,631 shares of the company’s stock after buying an additional 165,181 shares during the period. Vanguard Group Inc. owned 1.98% of Cerulean Pharma worth $1,151,000 at the end of the most recent reporting period. 33.19% of the stock is currently owned by hedge funds and other institutional investors.

Cerulean Pharma Company Profile

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

5 Day Chart for NASDAQ:CERU

Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.